anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A novel photocrosslinked polysaccharide which has low swelling properties an d high in vivo decomposability while retaining some degree of strength. It is a polysaccharide pseudo-sponge which is obtained by the crosslinking reaction of a photoreactive polysaccharide produced by introducing a photoreactive group into a polysaccharide and which has the low swelling properties and low dyeability with blue dextran shown under the following (I) and (II). (I) Whe n a test piece (thickness, 1 mm; length, 10 mm; width, 10 mm) having a solvent content of 96 wt.% is prepared, immersed in water for injection at room temperature for 1 hour, and then examined, the test piece has a degree of swelling as represented by the following equation of 125% or lower. [Numeric al formula 1] degree of swelling = {(S2-S1)/S1} .times. 100 (S1 represents the area before immersion and S2 represents the area after immersion, each area being calculated from the length and width dimensions of the test piece.) (I I) When a test piece (thickness, 1 mm; length, 20 mm; width, 10 mm) having a solvent content of 96 wt.% is prepared, immersed in a 0.5 g/mL aqueous solution of blue dextran having a weight-average molecular weight of 2,000,000, rinsed with water, and then hydrolyzed to prepare an aqueous solution having a concentration of 0.67 wt.% in terms of polysaccharide concentration, this aqueous solution has an absorbance of 0.15 or lower as measured at a wavelength of 620 nm.
Regain of function and improvement of motor skills is a major challenge in motor disorders in which spinal cord functions play a key role. The growing development of non-invasive brain stimulations in the past decade led to significant progress in the understanding of neuronal abnormalities in patients with movement disorders that opens up new vistas for experimental treatments. However, these treatments are currently limited due to their high cost and lack of possibility to use in outpatients. Recently, trans-spinal direct current stimulation (tsDCS) has emerged as a novel tool to modulate non-invasively spinal cord excitability. This may be an excellent alternative to epidural stimulation, the sole technique available up to now to alter spinal functions in an invasive fashion. The overall goal of this study is to assess the potential of tsDCS to restore spinal cord functions in patients with primary orthostatic tremor (POT), a disorder with little or no current therapeutic resources and high disability for patients.

Using a crossover, randomized, double-blinded approach, cathodal (2mA, 20 min) or sham tsDCS (with the active electrodes over the thoracic level and the reference electrode on the right shoulder) will be delivered to 15 patients with POT. The maximal time in upright position determined by a force platform, the cortical excitability assessed by transcranial magnetic stimulation (input / output curve of the tibialis anterior muscle and short-latency afferent inhibition) and EMG activities of lower extremity muscles will be measured before (PRE), immediately and 30 minutes after current offset (POST0 and POST30 respectively). Cathodal and sham tsDCS will be delivered in two different sessions with a washout period of at least 7 days. The investigators anticipate that cathodal tsDCS but not sham tsDCS will be able to modulate both sensory and motor functions in POT and will, in turn, lead to functional improvement.
Natural Extract from Whole Fruit of Banana (Musa Spp)., whether unripe or ripe, containing mainly natural Melatonin, Serotonin, Catecholamines and its precursors; amino acids tryptophan and tyrosine; mineral potassium, magnesium, phosphorous and antioxidants. Contains very minimal or no carbohydrates. Final extract is in liquid, semi solid or powder form. Extract is for mammals and animal use at doses 1 to 1,000mg in powder or equivalent to powder per day. Extract is used as nutritional supplement, medicine or adjuvant in liquid, gel, capsule, caplet or tablet form. Physical treatment, Enzymatic processes and resin extraction are mainly used for extraction. Food or pharmaceutical grade additives like preservatives or antioxidants are added for shelf life. Other extracts, vitamins, minerals and amino acids may be added for further enhancement of the effectiveness and usage. Extract is used for mammals and animals, in one or more of conditions, for mood elevation, reducing stress, anxiety and depression; increasing Basal Metabolism Rate (BMR), thermogenesis, obesity, hyperlipidemia, hypercholesterol, hypertension, diabetes, sleeping disorders, neurological disorder, muscular disorder, erectile dysfunction and to increase potassium content in the body.
Participants in this group have a life-time history of bulimia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa.
1,125,612. Coatings. PERMUTIT CO. Ltd. 17 March, 1966 [23 March, 1965], No. 12309/65. Headings B2E and B2K. [Also in Division C3] Substrates are coated with paints which comprise an emulsion of a terpolymer formed from a mixture of monomers comprising vinyl acetate and lesser proportions of the vinyl esters of a mixture of branched fatty acids containing a total of nine to eleven carbon atoms and of an alkyl acrylate, a dialkyl maleate or a dialkyl fumarate. In Examples sealed hardboard panels, asbestos and cement panels, sheets of mild steel and wallpaper are coated.
PURPOSE:To provide the titled remedy containing an alkylthiamine disulfide as a main component. CONSTITUTION:A remedy for trichophytosis can be produced by using the compound of formula (R1 is methyl, ethyl, propyl or butyl; R2 is methyl, ethyl, propyl, allyl or furfuryl) as a main component. The compound is a substance having the action of vitamin B1 and the remedying effect is originated from high absorptivity into skin, formation of remedying substance in the cuticle and development of sterilizing effect by the substance. Since the compound is a vitamin B1-activity substance, its safety (non-irritation, non-toxicity and free from side effect) is completely ascertained. EFFECT:Remarkable and sure remedying effect. The effect can be achieved within a short time.
Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
A method for producing viral gene delivery vehicles which can be transferred to pre-selected cell types by using targeting conjugates. The gene delivery vehicles comprise: 1) the gene of interest; and 2) a viral capsid or envelope carrying a member of a specific binding pair, the counterpart of which is not directly associated with the surface of the target cell. These vehicles can be rendered unable to bind to their natural cell receptor. The targeting conjugates include the counterpart member of the specific binding pair, linked to a targeting moiety which is a cell-type specific ligand (or fragments thereof). The number of the specific binding pair present on the viral vehicles can be, for example, an immunoglobulin binding moiety (e.g., capable of binding to a Fc fragment, protein A, protein G, FcR or an anti-Ig antibody), or biotin, avidin or streptavidin. The virus' outer membrane or capsid may contain a substance which mediates entrance of the gene delivery vehicle into the target cell. Due to the specificity of the ligand, the binding pair's high affinity, and the gene delivery vehicle's inability to be targeted when used alone, the universality of the method for gene delivery, together with its high cell type selectively can be achieved by using various targeting conjugates.
PURPOSE:To eliminate the bitter taste of the extract of Fomes japonicus, by adding a specific amount of beta-cyclodextrin to the Fomes japonicus extract. CONSTITUTION:1pt. of the extract of Fomes japonicus is added with >=0.8pt. of beta-cyclodextrin, the mixture is dispersed or dissolved in water, and water is evaporated to obtain Fomes japonicus extract free from bitter taste. As an alternative method, the Fomes japonicus extract is mixed directly with beta-cyclodextrin with a mixer. The obtained mixture can be used in any form such as powder, granule, pellet, solid, liquid, etc. Any additive may be incorporated thereto provided that it has no adverse effect to the object. Fomes japonicus is a kind of fungi belonging to Fomes genus, and its hot water extract is useful as a health food. It contains saccharides, lipids, proteins, etc.
PURPOSE:To obtain the subject foundamental cosmetics capable of ready carriage and having a low stimulation to the skin due to the absence of a surfactant by putting agar-agar capsules encapsulating a hydrophobic component for the cosmetics and sheets impregnated with an aqueous solution of a hydrophilic component for the cosmetics in a sealed container. CONSTITUTION:Agar-agar capsules 4 encapsulating a hydrophobic component 2 (e.g. fluid paraffin, silicone oil or vitamin E) for a cosmetics and sheets 6 impregnated with water or an aqueous solution 5 of a hydrophilic component (e.g. polyvalent alcohol, saccharides or mucopolysaccharides) for the cosmetics are put in a tightly sealed container 7. In the case where the above-mentioned cosmetics is subjected to use, a weak force is applied to the upper face of the sealed container or to the sheets taken out from the container so as to break the agar-agar capsules and to transfer the hydrophobic component to the impregnated sheet. By rubbing the skin with the above mentioned sheets, water or the aqueous solution of the hydrophilic component and the hydrophobic component are simultaneously applied.
FIELD: medicine, gastroenterology, phytotherapy, parapharmaceutical industry. SUBSTANCE: preparation for prophylaxis and accessory therapy in treatment of gastritis, duodenitis and colitis comprises milfoil leaves infusion dry concentrate, matricary flowers infusion dry concentrate, peppermint tincture dry concentrate, sea-buckthorn fruits syrup dry concentrate, dioecious nettle leaves extract dry concentrate, fenestrate Saint-John's-wort herb tincture dry concentrate and also starch, wheat bran, calcium state and sugar. Supplement shows the general tonic effect on function of alimentary tract. Invention can be used for prophylaxis and treatment of gastritis, duodenitis and colitis of different etiology. EFFECT: valuable medicinal properties of supplement. 1 tbl, 4 ex
A clinical case that demonstrates the development of human papilloma virus (HPV)-associated penile intraepithelial neoplasia (PIN), namely the erythematous form of bowenoid papulosis in a young patient, as well as a delay in making a correct diagnosis due to incorrect diagnostic tactics and low alertness of doctors regarding oncologic diseases, is presented in the article. Penile intraepithelial neoplasia is the histological term for precancerous lesions of the penis. Timeliness is important in the diagnosis of PIN, since currently there is a high morbidity and mortality associated with the progression to squamous cell penile carcinoma. From the morphologic and pathogenetic standpoints, HPV-negative (differentiated) and HPV-positive subtypes of PIN are divided. The latter includes Bowenoid papulosis, erythroplasia of Queyrat and Bowen's disease. It is important to carry out a differential diagnosis between these lesions, since the rate of development of penile cancer for erythroplasia of Queyrat is 30%, for Bowen's disease is 5% and for bowenoid papulosis is 1%.
Parent-child dyads will receive DINOSAUR, a group-based cognitive-behavioral therapy (CBT) intervention, adapted for young children and delivered via telehealth. This 14 week intervention teaches parents and children strategies to reduce anxiety and intolerance of uncertainty, an underlying construct of anxiety.
A pervasive view is that undifferentiated stem cells are alone responsible for generating all other cells and are the origins of cancer. However, emerging evidence demonstrates fully differentiated cells are plastic, can be coaxed to proliferate, and also play essential roles in tissue maintenance, regeneration, and tumorigenesis. Here, we review the mechanisms governing how differentiated cells become cancer cells. First, we examine the unique characteristics of differentiated cell division, focusing on why differentiated cells are more susceptible than stem cells to accumulating mutations. Next, we investigate why the evolution of multicellularity in animals likely required plastic differentiated cells that maintain the capacity to return to the cell cycle and required the tumor suppressor p53. Finally, we examine an example of an evolutionarily conserved program for the plasticity of differentiated cells, paligenosis, which helps explain the origins of cancers that arise in adults. Altogether, we highlight new perspectives for understanding the development of cancer and new strategies for preventing carcinogenic cellular transformations from occurring.
OBJECTIVE: To quantitate the impact of heart donation after circulatory death (DCD) donor utilization on both waitlist and post-transplant outcomes in the United States.
METHODS: The United Network for Organ Sharing database was queried to identify all adult waitlisted and transplanted candidates between October 18, 2018, and December 31, 2022. Waitlisted candidates were stratified according to whether they had been approved for donation after brain death (DBD) offers only or also approved for DCD offers. The cumulative incidence of transplantation was compared between the 2 cohorts. In a post-transplant analysis, 1-year post-transplant survival was compared between unmatched and propensity-score-matched cohorts of DBD and DCD recipients.
RESULTS: A total of 14,803 candidates were waitlisted, including 12,287 approved for DBD donors only and 2516 approved for DCD donors. Overall, DCD approval was associated with an increased sub-hazard ratio (HR) for transplantation and a lower sub-HR for delisting owing to death/deterioration after risk adjustment. In a subgroup analysis, candidates with blood type B and status 4 designation received the greatest benefit from DCD approval. A total of 12,238 recipients underwent transplantation, 11,636 with DBD hearts and 602 with DCD hearts. Median waitlist times were significantly shorter for status 3 and status 4 recipients receiving DCD hearts. One-year post-transplant survival was comparable between unmatched and propensity score-matched cohorts of DBD and DCD recipients.
CONCLUSIONS: The use of DCD hearts confers a higher probability of transplantation and a lower incidence of death/deterioration while on the waitlist, particularly among certain subpopulations such as status 4 candidates. Importantly, the use of DCD donors results in similar post-transplant survival as DBD donors.
The dosage of Dehydrated Alcohol Injection for therapeutic nerve or ganglion block varies from as little as 0.05 to 0.5 mL in trigeminal neuralgia to 0.5 to 1.0 mL per interspace for subarachnoid injections. Doses larger than 1.5 mL are seldom required. All injections should be made slowly and only after all steps have been taken to insure precise placement of the alcohol. A 1.0 mL tuberculin syringe is desirable to facilitate accurate measurement of the dose. Separate needles should be used for injection of successive interspaces or other sites. Since Dehydrated Alcohol Injection is hypobaric as compared to spinal fluid, proper positioning of the patient is essential to control localization of injections into the subarachnoid space.

When lesser concentrations of alcohol are used, larger volumes are usually injected. A dose of 2 mL of 45% alcohol has been used for injecting individual motor nerves, or from 1.5 to 4.0 mL for epidural injection in children with spastic cerebral palsy; 50 mL of 50% alcohol has been used for celiac plexus blockade.

The LD50 oral dose in rats is 13.7 g/kg.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.
Aerosolized pentamidine was as effective as intravenous pentamidine in treating PCP in animals. More of the pentamidine reached the lungs and less was found in the liver and kidney after pentamidine was given by aerosol than after an intravenous injection. This suggests that the toxicity of pentamidine may be less if given by aerosol than if given by the intravenous route.

Patients will inhale one dose of radiolabeled aerosol containing pentamidine, and an image of the lung will be taken immediately and then 24 hours later to determine the amount of pentamidine reaching the various areas of the lung. Patients will then undergo a bronchoalveolar lavage (BAL) in order to recover the PCP organism from the lung and to corroborate the diagnosis of PCP. If PCP organisms are detected, patients will be randomly assigned to aerosolized or intravenous pentamidine and treated for 21 days. Patients taking pentamidine by aerosol will repeat the radiolabeled aerosol study on day 9. The BAL will be repeated at the end of therapy for all patients. If patients do not improve within 9 days, they will be switched to another therapy. After completion of therapy, patients will be given the option of prophylactic therapy, i.e., doses of medication to prevent reinfection, for PCP. All patients will be carefully assessed every 4 weeks for 6 months whether they begin prophylactic therapy or not. Zidovudine (AZT) may not be taken during the 21-day trial because of the increased risk of side effects, but it can be resumed when PCP therapy is completed.
Patients in the experimental group will undertake a 12-week (semi)automated telecoaching program with the aim of enhancing their physical activity. The program uses a Fitbit wearable and a smartphone application that is developed for and tested to be effective for patients with COPD.
BACKGROUND: External Jugular Thrombophlebitis (EJT) is a rare clinical phenomenon with few reports in the literature, especially in the pediatric population. This is a report of an unusual case of right-sided EJT in a pediatric patient secondary to acute pharyngitis with sinusitis most prominent on the left side.
CASE PRESENTATION: A 13-year-old presented to the emergency department with worsening upper respiratory infectious (URI) symptoms and facial swelling, cough, throat pain, and emesis. The patient had traveled to Switzerland and received amoxicillin for strep throat 6 weeks before this hospitalization. Physical examination revealed nasal purulence, allodynia over the right side of the face without overlying erythema, and oropharyngeal exudate. CT scan revealed left-sided predominate sinusitis and right external jugular vein thrombosis. Blood cultures confirmed the presence of group A streptococcus infection. Treatment included IV antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), IV steroids, and anticoagulation. Follow-up imaging demonstrated improvement in thrombosis, cellulitis, and sinus disease. The patient was discharged on antibiotics for 6 weeks and anticoagulation for 10 weeks. Follow-up imaging at 6 months revealed no EJT, and medications were discontinued.
CONCLUSIONS: EJT is a rare condition, and to our knowledge, no reports of EJT with sinusitis most pronounced on the contralateral side have been published. Physicians will benefit from noting clinical signs of EJT such as facial edema, headache, erythema, and palpable neck mass, especially if these symptoms occur with URI symptoms refractory to treatment. The use of anticoagulation is controversial for internal jugular vein thrombosis, and while no guidelines for EJT exist, anticoagulation is likely not necessary save for severe complications.
Inactive LNAA tablets (placebos) are given to each participant in 3 multiple crossovers for a total exposure to the Inactive Comparator 3 times. The allocation is randomized within each cycle of two treatments (inactive/active). There are 3 total cycles for each participant. The placebo intervention is PreKUnil® placebo tablets.
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is an emerging major unmet need and one of the most significant clinic challenges in cardiology. The pathogenesis of HFpEF is associated with multiple risk factors. Hypertension and metabolic disorders associated with obesity are the 2 most prominent comorbidities observed in patients with HFpEF. Although hypertension-induced mechanical overload has long been recognized as a potent contributor to heart failure with reduced ejection fraction, the synergistic interaction between mechanical overload and metabolic disorders in the pathogenesis of HFpEF remains poorly characterized.
METHOD: We investigated the functional outcome and the underlying mechanisms from concurrent mechanic and metabolic stresses in the heart by applying transverse aortic constriction in lean C57Bl/6J or obese/diabetic B6.Cg-Lepob/J (ob/ob) mice, followed by single-nuclei RNA-seq and targeted manipulation of a top-ranked signaling pathway differentially affected in the 2 experimental cohorts.
RESULTS: In contrast to the post-transverse aortic constriction C57Bl/6J lean mice, which developed pathological features of heart failure with reduced ejection fraction over time, the post-transverse aortic constriction ob/ob mice showed no significant changes in ejection fraction but developed characteristic pathological features of HFpEF, including diastolic dysfunction, worsened cardiac hypertrophy, and pathological remodeling, along with further deterioration of exercise intolerance. Single-nuclei RNA-seq analysis revealed significant transcriptome reprogramming in the cardiomyocytes stressed by both pressure overload and obesity/diabetes, markedly distinct from the cardiomyocytes singularly stressed by pressure overload or obesity/diabetes. Furthermore, glucagon signaling was identified as the top-ranked signaling pathway affected in the cardiomyocytes associated with HFpEF. Treatment with a glucagon receptor antagonist significantly ameliorated the progression of HFpEF-related pathological features in 2 independent preclinical models. Importantly, cardiomyocyte-specific genetic deletion of the glucagon receptor also significantly improved cardiac function in response to pressure overload and metabolic stress.
CONCLUSIONS: These findings identify glucagon receptor signaling in cardiomyocytes as a critical determinant of HFpEF progression and provide proof-of-concept support for glucagon receptor antagonism as a potential therapy for the disease.
A method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases and fibromyalgia. A compound effective to increase neuronal metabolism of histamine to a histamine H 2  agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration. The compound is selected from the group consisting of histamine M-methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and histamine H 3  antagonists. The histamine M-methyltransferase may be administered to increase neuronal metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A agonist may be administered so as to increase neuronal metabolism of telemethylhistamine to an H 2  agonist. Separately or in conjunction with the others, the histamine H 3  antagonist may be administered so as to inhibit metabolism of the telemethylhistamine to an H 3  agonist, thereby increasing metabolism of the telemethylhistamine to an H 2  agonist. The increased histamine H 2  agonist levels reduce demyelination and the symptoms that are associated with these conditions.